The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
The Translation of Cell-Based Therapies: Clinical Landscape and Manufacturing Challenges
Open accessAbstract
Cell-based therapies have the potential to make a large contribution toward currently unmet patient need and thus effective manufacture of these products is essential. Many challenges must be overcome before this can become a reality and a better definition of the manufacturing requirements for cell-based products must be obtained. The aim of this study is to inform industry and academia of current cell-based therapy clinical development and to identify gaps in their manufacturing requirements. A total of 1342 active cell-based therapy clinical trials have been identified and characterized based on cell type, target indication and trial phase. Multiple technologies have been assessed for the manufacture of these cell types in order to facilitate product translation and future process development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
The ClinicalTrials.gov Results Database — Update and Key Issues
Zarin, D. A., Tse, T., Williams, R. J., Califf, R. M., & Ide, N. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1012065 · Cited by 838
Scalable Stirred-Suspension Bioreactor Culture of Human Pluripotent Stem Cells
Kehoe, D. E., Jing, D., Lock, L. T., & Tzanakakis, E. S. (2010) · Tissue Engineering Part A · doi:10.1089/ten.tea.2009.0454 · Cited by 264
Cited by
Ho-Shui-Ling, A., Bolander, J., Rustom, L. E., Johnson, A. W., Luyten, F. P., & Picart, C. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.07.017 · Cited by 961
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637
Villa, C. H., Anselmo, A. C., Mitragotri, S., & Muzykantov, V. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.007 · Cited by 397
Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency
Willis, G. R., Kourembanas, S., & Mitsialis, S. A. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00063 · Cited by 257
New cell sources for T cell engineering and adoptive immunotherapy
Themeli, M., Rivière, I., & Sadelain, M. (2015) · Cell stem cell · doi:10.1016/j.stem.2015.03.011 · Cited by 179
Metadata
- Authors
- Heathman, T. R., Nienow, A. W., McCall, M. J., Coopman, K., Kara, B., & Hewitt, C. J.
- Venue
- Regenerative Medicine
- Publisher
- Informa UK Limited
- Published
- 2015-01
- Volume
- 10
- Issue
- 1
- Pages
- 49-64
- ISSN
- 1746-0751 (ISSN-L)
- 1746-076X
- OpenAlex
- W2155825917
- Cited by
- 297
- References
- 5
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Translation of Cell-Based Therapies: Clinical Landscape and Manufacturing Challenges. https://app.cochat.ai/papers/10.2217/rme.14.73
- The paper
- Heathman, T. R., Nienow, A. W., McCall, M. J., Coopman, K., Kara, B., & Hewitt, C. J. (2015). The Translation of Cell-Based Therapies: Clinical Landscape and Manufacturing Challenges. Regenerative Medicine. https://doi.org/10.2217/rme.14.73
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.